{"groups":[{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 50 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 50 mg once daily continuously.","id":"FG000","title":"Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 100 mg sunvozertinib, followed by a 7-day washout period. Then, they received 100 mg sunvozertinib once daily continuously.","id":"FG001","title":"Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 200 mg sunvozertinib, followed by a 7-day washout period. Then, they received 200 mg sunvozertinib once daily continuously.","id":"FG002","title":"Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 300 mg sunvozertinib, followed by a 7-day washout period. Then, they received 300 mg sunvozertinib once daily continuously.","id":"FG003","title":"Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 400 mg sunvozertinib, followed by a 7-day washout period. Then, they received 400 mg sunvozertinib once daily continuously.","id":"FG004","title":"Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg"},{"description":"Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 200 mg once daily dosing in the fasted state continuously.","id":"FG005","title":"Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State"},{"description":"Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 300 mg once daily dosing in the fasted state continuously.","id":"FG006","title":"Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 200 mg once daily dosing with a low-fat meal continuously.","id":"FG007","title":"Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.","id":"FG008","title":"Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, treatment naïve. Patients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.","id":"FG009","title":"Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, were refractory to, relapsed from, or intolerant to previous amivantamab treatment.\n\nNo patient was enrolled into this cohort.","id":"FG010","title":"Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive a single dose of sunvozertinib 300 mg under the High-Fat Meal condition, followed by a 7-day washout and crossed to receive a single dose of sunvozertinib 300 mg under the Fasted condition, followed by a 7-day washout. Then patients received sunvozertinib 300 mg once daily continuously.","id":"FG011","title":"Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive a single dose of sunvozertinib 300 mg under the Fasted condition, followed by a 7-day washout and crossed to receive a single dose of sunvozertinib 300 mg under the High-Fat Meal condition, followed by a 7-day washout. Then patients received sunvozertinib 300 mg once daily continuously.","id":"FG012","title":"Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized to receive sunvozertinib 200 mg once daily continuously.","id":"FG013","title":"Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized to receive sunvozertinib 300 mg once daily continuously.","id":"FG014","title":"Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"4"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"33"},{"groupId":"FG014","numSubjects":"40"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"3"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"3"},{"groupId":"FG014","numSubjects":"9"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"1"},{"groupId":"FG014","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"}],"type":"site terminated by sponsor or non compliance"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"14"},{"groupId":"FG007","numSubjects":"14"},{"groupId":"FG008","numSubjects":"7"},{"groupId":"FG009","numSubjects":"31"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"5"},{"groupId":"FG012","numSubjects":"7"},{"groupId":"FG013","numSubjects":"91"},{"groupId":"FG014","numSubjects":"111"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"8"},{"groupId":"FG007","numSubjects":"10"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"24"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"4"},{"groupId":"FG012","numSubjects":"6"},{"groupId":"FG013","numSubjects":"54"},{"groupId":"FG014","numSubjects":"61"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"4"},{"groupId":"FG008","numSubjects":"4"},{"groupId":"FG009","numSubjects":"7"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"37"},{"groupId":"FG014","numSubjects":"50"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}